Searchable abstracts of presentations at key conferences in oncology
Oncology Abstracts (2019) 1 P038 | DOI: 10.1530/oncolabs.1.P038

PacRim7 7th PacRim Meeting Poster Presentations (1) (52 abstracts)

Flicking the switch off, targeting MCL-1 in the treatment of breast and prostate cancer

L Castillo 1 , S George 1 , H-M Lin 1 , N Yeung 1 , A Mawson 1 , AI Young 1 , AM Law 1 , J Hastings 1 , D Gallego-Ortega 1, , N Deng 1 , D Croucher 1, , A Swarbrick 1, , L Horvath 3, , CJ Ormandy 1, & SR Oakes 1,

5 views


1The Kinghorn Cancer Centre, Cancer Research Division, Garvan Institute of Medical Research, Darlinghurst, NSW, 2010, Australia; 2St Vincent’s Clinical School, Faculty of Medicine, UNSW Sydney, Darlinghurst, NSW, 2010, Australia; 3Chris O’Brien Lifehouse, Sydney, Australia; 4Garvan Institute of Medical Research, Sydney, Australia; 5University of NSW, Sydney, Australia; 6University of Sydney, Sydney, Australia.


The ability to survive is essential for carcinogenesis. We previously showed that in to addition promoting cancer cell survival, Myeloid Cell Leukemia 1 (MCL-1) regulates cancer cell invasion possibly via direct regulation of the cytoskeletal protein Cofilin and via modulation of the output of the SRC family kinase pathway. We also showed that dual inhibition of MCL-1 and SRC family kinases was effective in suppressing metastasis of breast cancer intraductal xenografts made from immortalized triple negative breast cancer cells. We are now exploring the potential of targeting MCL-1 alone or in combination with dasatinib and taxane-based cytotoxic therapy in clinically relevant models of metastatic breast and prostate cancer. Here we will report the findings from this study and the progress of a systems biology approach to predicting response.

Volume 1

7th International Pacific Rim (PacRim) Breast and Prostate Cancer Meeting


17 Mar 2019 - 20 Mar 2019

PacRim Breast and Prostate Cancer Group 

Browse other volumes

Article tools

My recent searches

No recent searches.